<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04002895</url>
  </required_header>
  <id_info>
    <org_study_id>18154A</org_study_id>
    <nct_id>NCT04002895</nct_id>
  </id_info>
  <brief_title>What the Body Does to Foliglurax in Healthy Volunteers</brief_title>
  <acronym>Foliglurax</acronym>
  <official_title>Interventional, Open-label, Single-dose Study Investigating the Absorption, Metabolism and Excretion (AME) of Foliglurax (Lu AF99757) Following Oral Dosing of 14C-foliglurax to Healthy Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates how the body takes up and gets rid of foliglurax after swallowing a
      liquid dose.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Six healthy men will swallow a liquid dose of 80 mg that is labelled with a small dose of
      radioactive tracer. Blood, urine and faeces will be collected to measure how much of the
      radioactivity gets into the blood stream and ends up in the urine and faeces. It is also
      measured how the body gets rid of the radioactivity and how quickly.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 27, 2019</start_date>
  <completion_date type="Actual">August 8, 2019</completion_date>
  <primary_completion_date type="Actual">August 1, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total amount of radioactivity excreted</measure>
    <time_frame>Before dosing until day 11</time_frame>
    <description>Cumulative amount of radioactivity excreted in urine and faeces</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-inf) foliglurax</measure>
    <time_frame>From day 1 until day 11</time_frame>
    <description>Area under the plasma concentration time curve from zero to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax foliglurax</measure>
    <time_frame>From day 1 until day 11</time_frame>
    <description>Maximum observed plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F foliglurax</measure>
    <time_frame>From Day 1 until Day 11</time_frame>
    <description>Oral clearance for foliglurax in plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total recovery of the administered dose</measure>
    <time_frame>Before dosing until day 11</time_frame>
    <description>% of dose in urine and faeces</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Foliglurax</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Foliglurax</intervention_name>
    <description>Single oral dose of 80 mg [14C]-foliglurax(93ÂµCi/3.44 MBq), 1mg/mL oral solution (prepared from [14C]-foliglurax powder for oral solution)</description>
    <arm_group_label>Foliglurax</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Healthy men with a body mass index (BMI) of 19-30 kg/m2 (inclusive), and with a body
        weight of minimum 60 kg at the Screening Visit.

        Exclusion Criteria:

        - The subject has or has had any clinically significant immunological, cardiovascular,
        respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological, haematological,
        dermatological, venereal, neurological, or psychiatric disease or other major disorder.

        Other inclusion and exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@Lundbeck.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GB1050 Covance</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>June 27, 2019</study_first_submitted>
  <study_first_submitted_qc>June 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2019</study_first_posted>
  <last_update_submitted>November 1, 2019</last_update_submitted>
  <last_update_submitted_qc>November 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

